Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | Bioxyne Ltd (BXN.ASX) |
|---|---|
| Release Time | 28 Jan 2025, 9:20 a.m. |
| Price Sensitive | Yes |
Bioxyne Ltd reports record Q2 revenue and positive cash flow
- $6.1 million Q2 revenue, up 77% on Q1 and 310% on Q2 FY2024
- $12.6 million revenue H1 FY 2025, up 267% on previous half
- Positive operating cash flow of $1.5 million for the quarter
Bioxyne Limited (ASX:BXN), an Australian-headquartered international consumer health and pharmaceutical company, has reported its quarterly activities for the second quarter of the 2025 financial year. The company achieved a record second quarter trading, continuing on the outstanding result of its previous Q1 trading. This result was driven by several major contracts, a growing customer base, and an expanding product range. The standout in the Group continues to be Breathe Life Science (BLS) Australia, which was granted its Good Manufacturing Practice (GMP) Licence to manufacture medical cannabis products, as well as Psilocybin and MDMA, by the Therapeutic Goods Administration (TGA) in February 2024. The company reported $6.1 million in Q2 revenue, up 77% on Q1 and a 310% increase on Q2 FY2024. H1 FY 2025 revenue reached $12.6 million, up 267% on the previous half. The company also achieved positive operating cash flow of $1.5 million for the quarter, with cash receipts of $7.4 million. Bioxyne invested approximately $1.3 million in H1 FY2025 to increase its manufacturing capacity, which will drive further revenue growth in the second half of FY2025. The company expects to shortly receive ARTG Listing approval for the export of its Dr Watson Pharmaceutical products to the UK and is also completing a business case for establishing a proposed GMP manufacturing facility in Europe to meet local demand.
The company is projecting revenue growth in individual product categories in the next two quarters of between 30% to 50%.
The company is focused on growing its manufacturing customer base, growing market share for its Dr Watson® branded pharmaceutical products in Australia, growing the Dr Watson branded health and wellness products in Europe, and the introduction of its proprietary PCC probiotic product into its existing global distribution channels.